Clinical trial NCT00995722: Efficacy of Prednisone In the Treatment of Ocular Myasthenia
Official title: Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Ocular Myasthenia Gravis
Keywords: Ocular myasthenia gravis
Prednisone
Steroids
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: University of Miami
name: University of Rochester
First posted: 2009-10-15
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and tolerability of prednisone in patients diagnosed with ocular myasthenia.

Funding Source - FDA OOPD

Detailed description: The purpose of this study is to learn two things about prednisone in patients with ocular myasthenia. The first thing we aim to learn is whether or not prednisone is effective in improving the symptoms of double vision and drooping eyes that are experienced by patients with ocular myasthenia. The second thing we aim to learn is whether we can find a dose of prednisone that is well tolerated and safe. The overall goal is to find out whether a dose of prednisone that is safe and well tolerated is also effective in improving the symptoms of ocular myasthenia.

After completing screening assessments to confirm eligibility, all participants will receive treatment with pyridostigmine. If a participant's symptoms do not resolve within the first month while being treated with pyridostigmine, they will be randomized to receive prednisone or placebo. The amount of study medication a participant receives will depend on how their symptoms respond to the medication and if they experience any side effects.

After four months, participants that continue to have symptoms of ocular myasthenia and do not have side effects will receive open label high dose prednisone. Participants that no longer have symptoms will taper their dose of study drug in a double-blind fashion.

Eligibility criteria: Inclusion Criteria:

* Weakness confined to the extra-ocular muscles, eyelid levator and eye closure with an ocular-QMG1 score ≥ 1
* At least one of the following combinations of abnormal diagnostic testing: a) Elevated acetylcholine receptor antibody titers, (b) Abnormal repetitive nerve stimulation (\> 10% decrement following slow repetitive nerve stimulation) of any nerve-muscle pair, (c) Abnormal jitter on single fiber or concentric needle electromyography in any muscle, (d) Positive ice test and brain MRI that demonstrates no central nervous system pathology that mimics ocular myasthenia, or (e) Positive Tensilon test and brain MRI that demonstrate no central nervous system pathology that mimics ocular myasthenia
* Either no prior treatment with pyridostigmine, or participant has persistent ocular symptoms that are functionally limiting or troublesome despite treatment with pyridostigmine.
* Age 18 years or older, male or female
* Capable of providing informed consent and complying with study procedures
* Identifiable primary care physician to assist with management of medical complications that may arise as a consequence of steroid therapy
* Willing to be randomized to a trial of prednisone or placebo if symptoms respond inadequately to pyridostigmine.

Exclusion Criteria:

* Disease duration (time since symptom onset) \> 5 years
* Treatment with prednisone or other corticosteroids within 90 days of randomization
* Treatment with azathioprine, cyclosporine, mycophenolate mofetil or other immune suppressive medication since onset of MG unless dosages of these medications and/or duration of therapy with these medications are clinically insignificant in the judgment of the PI
* Intravenous immunoglobulin or plasma exchange within 90 days of randomization
* Prior thymectomy or history of thymoma
* Contraindication to steroids (poorly controlled diabetes, glaucoma or hypertension, history of prior steroid intolerance, obesity \[BMI \> 39.9kg/m2\] or a history of osteoporotic fracture)
* Pregnant or lactating
* Renal failure, active thyroid or hepatocellular disease, chronic infection, poorly controlled cardiac disease, unstable psychiatric illness, untreated major depression or any other illness that would, in the opinion of the treating neurologist, make it unsafe for the patient to participate in the trial
* Receipt of another investigational drug within 30 days of Screening

Primary outcomes:
measure: Treatment Failure
timeFrame: 4 months
Secondary outcomes:
measure: Change in Ocular Quantitative Myasthenia Score From Baseline to Week 16
timeFrame: 4 months
measure: Change in Quality of Life as Measured by the NEI-VFQ-25 Measures
timeFrame: 4 months
measure: Change in Quality of Life as Measured by the MG-QOL-15 Score
timeFrame: 4 Months
measure: Change in Quality of Life as Measured by the 10-Item Neuro-ophthalmological Supplement to the NEI-VFQ-25
timeFrame: 4 months
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
city: Buffalo
country: United States
facility: University at Buffalo, Buffalo General Medical Center
state: New York
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
city: Burlington
country: United States
facility: University of Vermont
state: Vermont
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
city: Edmonton
country: Canada
facility: University of Alberta Hospital
state: Alberta
city: Toronto
country: Canada
facility: Toronto General Hospital
state: Ontario
Study officials:
affiliation: University of Miami
name: Michael Benatar, MBChB, DPhil
role: PRINCIPAL_INVESTIGATOR
affiliation: State University of New York at Buffalo
name: Gil Wolfe, MD
role: STUDY_DIRECTOR
affiliation: Duke University
name: Donald Sanders, MD
role: STUDY_DIRECTOR
References: